CD4 and rheumatoid arthritis: The participation of CD4+ T cells in the pathogenesis of RA, namely by influencing other key cellular mediators of the disease (such as B cells or macrophages), has prompted the development of therapeutic strategies targeting this lymphocyte population [10], [11], [12], [13].